Veru (VERU) Stock Price, News & Analysis

Company Overview

Veru Inc. is a biopharmaceutical company focused on developing medicines for oncology and metabolic diseases. The company’s pipeline includes therapies intended to address cancer-related muscle wasting, obesity, and other conditions associated with the loss of lean body mass and physical function.

Veru’s principal investigational product is enobosarm, an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function in patients with cancer-related wasting and obesity. The company has also developed sabizabulin, an oral treatment candidate previously evaluated in prostate cancer and in hospitalized patients with COVID-19.

The company was formerly known as The Female Health Company and changed its name to Veru Inc. in 2017 as it expanded beyond its historical women’s health business. Its earlier commercial operations included the FC2 female condom, which was distributed internationally. Veru is headquartered in Miami, Florida, and is led by Mitchell S. Steiner, M.D., who serves as chairman and chief executive officer.

Key Stats

• Today's Range: $2.07 to $2.17
• 50-Day Range: $2.06 to $2.75
• 52-Week Range: $2.04 to $7.33
• Volume: 15,651 shs
• Average Volume: 666,443 shs
• Market Capitalization: $36.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.50
• Consensus Rating: Moderate Buy

Veru Stock Analysis - MarketRank™

Veru scored higher than 58% of companies evaluated by MarketBeat, and ranked 414th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veru has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Veru has a consensus price target of $24.50, representing about 1,055.7% upside from its current price of $2.12.

Amount of Analyst Coverage

Veru has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Veru are expected to decrease in the coming year, from ($1.04) to ($1.13) per share.

Price to Book Value per Share Ratio

Veru has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.25% of the float of Veru has been sold short.

Short Interest Ratio / Days to Cover

Veru has a short interest ratio ("days to cover") of 13.25, which indicates bearish sentiment.

Change versus previous month

Short interest in Veru has recently increased by 2.29%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veru does not currently pay a dividend.

Dividend Growth

Veru does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.90

News Sentiment

Veru has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Veru this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for VERU on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

6 people have added Veru to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $4,842.00 in company stock, which represents 0.0134% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Veru insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,842.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 11/11/2026
• Next Earnings (Estimated): 11/26/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:VERU
• CIK: 863894
• Web: www.verupharma.com
• Phone: (312) 595-9123
• Fax: 312-595-9122
• Employees: 20
• Year Founded: 1896

Price Target and Rating

• Average Price Target for Veru: $24.50
• High Price Target: $25.00
• Low Price Target: $24.00
• Potential Upside/Downside: +1,055.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.58%
• Return on Assets: -35.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.42
• Quick Ratio: 4.42

Sales & Book Value

• Annual Sales: $16.89 million
• Price / Sales: 2.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.25 per share
• Price / Book: 1.70

Miscellaneous

• Outstanding Shares: 17,050,000
• Free Float: 14,629,000
• Market Cap: $36.15 million
• Optionable: Optionable
• Beta: -1.20